These data collectively demonstrated that the SSc pathologic microenvironment can deeply impair different lymphangiogenesis steps, presumably by downregulating the pro-lymphangiogenic VEGFR-3/NRP-2 signaling [41]. This evidence concerns the gene FLT4 and systemic sclerosis.